# Kamada Ltd. (KMDA)

Source: https://www.quantisnow.com/company/KMDA
Generated: 2026-11-12T07:44:22.823Z

- Ticker: KMDA
- Exchange: NASDAQ
- Sector: Health Care
- Industry: Biotechnology: Pharmaceutical Preparations
- IPO year: 2013
- SEC CIK: 0001567529
- Website: kamada.com

## About

Kamada Ltd. develops, produces, and markets plasma-derived protein therapeutics for orphan indications. It operates in two segments, Proprietary Products and Distribution. The company offers Glassia for use in chronic augmentation and maintenance therapy in adults with emphysema due to congenital Alpha-1 Antitrypsin (AAT) deficiency. It also provides KamRAB for prophylaxis of rabies disease; KamRho (D) IM to treat prophylaxis of hemolytic disease of newborns; KamRho (D) IV for immune thermobocytopunic purpura; and snake bite antiserum to treat snake bites by the vipera palaestinae and echis coloratus. In addition, the company distributes Bramitob to manage chronic pulmonary infection; FOSTER to treat asthma; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; IVIG 5% for the treatment of various immunodeficiency-related conditions; AeroBika, an OPEP device; Varitect, a varicella zoster immunoglobulin; Zutectra and Hepatect CP for the prevention of hepatitis B virus; Megalotect, a CMV immunoglobulin; and RUCONEST for the treatment of acute angioedema attacks in adults with hereditary angioedema. Further, it distributes Heparin sodium injection to treat thrombo-embolic disorders; Albumin and Albumin 4% for maintenance of blood plasma; and coagulation factors comprising Factor VIII and Factor IX, as well as IXIARO vaccine. It markets its products through strategic partners in the United States, as well as through distributors internationally. Kamada Ltd. has strategic partnerships with Takeda Pharmaceutical Company Limited; PARI GmbH; and Kedrion Biopharma. The company was incorporated in 1990 and is headquartered in Rehovot, Israel.

## Latest KMDA news and filings

- 2026-11-09 12:05 UTC [SEC Form 6-K] [SEC Form 6-K filed by Kamada Ltd.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-kamada-ltd-6780153)
- 2026-11-09 12:02 UTC [Earnings Date] [Kamada Reports Record-High First Nine Months 2026 Financial Results; Increases 2026 Annual Guidance and Projects Double-Digit Growth in Revenues and Profitability in 2027](https://www.quantisnow.com/insight/kamada-reports-record-high-first-nine-months-2026-financial-results-increases-6780131)
- 2026-11-09 12:00 UTC [Dividends] [Kamada Declares Cash Dividend of $0.14 Per Share; The Company Continues its Record-High Year](https://www.quantisnow.com/insight/kamada-declares-cash-dividend-of-014-per-share-the-company-6780042)
- 2026-11-02 12:00 UTC [SEC Form 6-K] [SEC Form 6-K filed by Kamada Ltd.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-kamada-ltd-6766036)
- 2026-11-02 12:00 UTC [Earnings Date] [Kamada to Announce Third Quarter and Nine Months Ended September 30, 2026, Financial Results on November 9, 2026](https://www.quantisnow.com/insight/kamada-to-announce-third-quarter-and-nine-months-ended-september-6765998)
- 2026-10-19 11:00 UTC [Conference Announcement] [Kamada Announces Participation in the Stifel 2026 Healthcare Conference and the Jefferies Global Healthcare Conference in London During November 2026](https://www.quantisnow.com/insight/kamada-announces-participation-in-the-stifel-2026-healthcare-conference-and-6750055)
- 2026-10-06 11:00 UTC [SEC Form 6-K] [SEC Form 6-K filed by Kamada Ltd.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-kamada-ltd-6738067)
- 2026-10-06 11:00 UTC [Kamada Announces Expansion of Biosimilars Portfolio with the Launch of Two Additional Products in Israel](https://www.quantisnow.com/insight/kamada-announces-expansion-of-biosimilars-portfolio-with-the-launch-of-6738033)
- 2026-10-05 20:00 UTC [SEC Form 6-K] [SEC Form 6-K filed by Kamada Ltd.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-kamada-ltd-6736647)
- 2026-09-29 13:27 UTC [SEC Form 4] [SEC Form 4 filed by Director Asher-Topilsky Lilach](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-asher-topilsky-lilach-6728867)
- 2026-09-29 13:13 UTC [SEC Form 4] [SEC Form 4 filed by Director Davidi Ishay](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-davidi-ishay-6728834)
- 2026-09-29 13:08 UTC [SEC Form 4] [SEC Form 4 filed by Director Botzer Uri](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-botzer-uri-6728824)
- 2026-09-25 10:23 UTC [SEC Form 4] [SEC Form 4 filed by Chief Executive Officer London Amir](https://www.quantisnow.com/insight/sec-form-4-filed-by-chief-executive-officer-london-amir-6725958)
- 2026-09-24 19:28 UTC [SEC Form 4] [SEC Form 4 filed by VP, BD and Strategic Programs Gorelik Boris](https://www.quantisnow.com/insight/sec-form-4-filed-by-vp-bd-and-strategic-programs-6725280)
- 2026-09-24 19:22 UTC [SEC Form 4] [SEC Form 4 filed by Director Payorski Lilach](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-payorski-lilach-6725279)
- 2026-09-24 19:20 UTC [SEC Form 4] [SEC Form 4 filed by VP Human Resources Reshef Liron](https://www.quantisnow.com/insight/sec-form-4-filed-by-vp-human-resources-reshef-liron-6725278)
- 2026-09-24 11:00 UTC [SEC Form 4] [SEC Form 4 filed by Kamada Ltd.](https://www.quantisnow.com/insight/sec-form-4-filed-by-kamada-ltd-6724781)
- 2026-09-24 11:00 UTC [SEC Form 4] [SEC Form 4 filed by Kamada Ltd.](https://www.quantisnow.com/insight/sec-form-4-filed-by-kamada-ltd-6724779)
- 2026-09-23 20:04 UTC [SEC Form 4] [SEC Form 4 filed by VP, General Counsel Livneh Nir](https://www.quantisnow.com/insight/sec-form-4-filed-by-vp-general-counsel-livneh-nir-6724129)
- 2026-09-23 20:00 UTC [SEC Form 4] [SEC Form 4 filed by VP Regulatory Affairs Pinchuk Orit](https://www.quantisnow.com/insight/sec-form-4-filed-by-vp-regulatory-affairs-pinchuk-orit-6724105)
- 2026-09-23 19:58 UTC [SEC Form 4] [SEC Form 4 filed by Director Recanati Leon](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-recanati-leon-6724087)
- 2026-09-23 19:53 UTC [SEC Form 4] [SEC Form 4 filed by Chief Financial Officer Orlev Chaime](https://www.quantisnow.com/insight/sec-form-4-filed-by-chief-financial-officer-orlev-chaime-6724082)
- 2026-09-23 17:31 UTC [SEC Form 4] [SEC Form 4 filed by VP, Operations Nir Eran](https://www.quantisnow.com/insight/sec-form-4-filed-by-vp-operations-nir-eran-6724025)
- 2026-09-23 17:01 UTC [SEC Form 4] [SEC Form 4 filed by Director Itshayek Assaf](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-itshayek-assaf-6724019)
- 2026-09-23 16:58 UTC [SEC Form 4] [SEC Form 4 filed by Director Dekel Benjamin](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-dekel-benjamin-6724014)
- 2026-09-23 16:54 UTC [SEC Form 4] [SEC Form 4 filed by VP, Marketing & Sales Neheman Hanni](https://www.quantisnow.com/insight/sec-form-4-filed-by-vp-marketing-sales-neheman-hanni-6724013)
- 2026-09-23 11:37 UTC [SEC Form 4] [SEC Form 4 filed by VP Quality Brenner Yael](https://www.quantisnow.com/insight/sec-form-4-filed-by-vp-quality-brenner-yael-6723612)
- 2026-09-23 11:14 UTC [SEC Form 4] [SEC Form 4 filed by Director Tsur David](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-tsur-david-6723592)
- 2026-09-17 15:40 UTC [SEC Form 4] [VP Quality Brenner Yael exercised 26,964 units of Ordinary Shares at a strike of $5.93 and covered exercise/tax liability with 7,395 units of Ordinary Shares (SEC Form 4) (for tax liability)](https://www.quantisnow.com/insight/vp-quality-brenner-yael-exercised-26964-units-of-ordinary-shares-6718803)
- 2026-09-17 15:37 UTC [SEC Form 4] [VP, General Counsel Livneh Nir exercised 10,000 units of Ordinary Shares at a strike of $5.37 and covered exercise/tax liability with 3,459 units of Ordinary Shares (SEC Form 4) (withholding obligation)](https://www.quantisnow.com/insight/vp-general-counsel-livneh-nir-exercised-10000-units-of-ordinary-6718801)
- 2026-09-17 15:33 UTC [SEC Form 4] [Director Tsur David sold $186,725 worth of Ordinary Shares (22,827 units at $8.18), decreasing direct ownership by 5% to 407,929 units (SEC Form 4)](https://www.quantisnow.com/insight/director-tsur-david-sold-186725-worth-of-ordinary-shares-22827-6718798)
- 2026-09-17 11:00 UTC [SEC Form 6-K] [SEC Form 6-K filed by Kamada Ltd.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-kamada-ltd-6718358)
- 2026-09-17 11:00 UTC [CDC Highlights Significant Increase in U.S. Rabies Exposures and Anti-Rabies Immunoglobulin Utilization; Kamada Confirms Sufficient KedRAB® Supply to Meet Increased Demand](https://www.quantisnow.com/insight/cdc-highlights-significant-increase-in-us-rabies-exposures-and-anti-rabies-6718334)
- 2026-09-16 04:15 UTC [SEC Form EFFECT] [SEC Form EFFECT filed by Kamada Ltd.](https://www.quantisnow.com/insight/sec-form-effect-filed-by-kamada-ltd-6716805)
- 2026-09-11 15:29 UTC [SEC Form 4] [Director Tsur David sold $1,463,734 worth of Ordinary Shares (177,173 units at $8.26), decreasing direct ownership by 29% to 430,756 units (SEC Form 4)](https://www.quantisnow.com/insight/director-tsur-david-sold-1463734-worth-of-ordinary-shares-177173-6712699)
- 2026-09-10 11:00 UTC [SEC Form 6-K] [SEC Form 6-K filed by Kamada Ltd.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-kamada-ltd-6710774)
- 2026-09-10 11:00 UTC [Conference Announcement] [Kamada to Present at the H.C. Wainwright 28th Annual Global Investment Conference](https://www.quantisnow.com/insight/kamada-to-present-at-the-hc-wainwright-28th-annual-global-6710759)
- 2026-09-09 11:00 UTC [SEC Form F-3 filed by Kamada Ltd.](https://www.quantisnow.com/insight/sec-form-f-3-filed-by-kamada-ltd-6709188)
- 2026-09-08 11:00 UTC [SEC Form 4] [VP Quality Brenner Yael exercised 3,036 units of Ordinary Shares at a strike of $5.94 and covered exercise/tax liability with 865 units of Ordinary Shares (SEC Form 4) to cover taxes](https://www.quantisnow.com/insight/vp-quality-brenner-yael-exercised-3036-units-of-ordinary-shares-6707382)
- 2026-09-08 11:00 UTC [SEC Form 4] [Director Tsur David exercised 49,000 units of Ordinary Shares at a strike of $6.71 and covered exercise/tax liability with 9,166 units of Ordinary Shares (SEC Form 4) (for withholding tax)](https://www.quantisnow.com/insight/director-tsur-david-exercised-49000-units-of-ordinary-shares-at-6707378)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/KMDA
- Earnings history: https://www.quantisnow.com/earnings/KMDA
- Dividend history: https://www.quantisnow.com/dividends/KMDA
- Insider transactions: https://www.quantisnow.com/insiders/KMDA
- Options chain: https://www.quantisnow.com/options/KMDA
- SEC 8-K filings only: https://www.quantisnow.com/company/KMDA/8-k
- RSS and alerts for KMDA: https://www.quantisnow.com/docs/rss-feeds.md